All BIIB Content

Biogen Inc (BIIB) Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting

Biogen Inc (NASDAQ: BIIB) FY 2026 Other Release

March 19, 20261 min read

Biogen Inc (BIIB) Sec Form 8K

Biogen Inc (NASDAQ: BIIB) Sec Form 8K

March 12, 20261 min read

Biogen Inc (BIIB) Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy

Biogen Inc (NASDAQ: BIIB) FY 2026 Other Release

March 11, 20261 min read

Biogen Inc (BIIB) The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome

Biogen Inc (NASDAQ: BIIB) FY 2026 Other Release

March 4, 20261 min read

Biogen Inc (BIIB) Sec Form 8K

Biogen Inc (NASDAQ: BIIB) Sec Form 8K

February 12, 20261 min read

Biogen Inc (BIIB) Biogen Announces Board Chair Transition

Biogen Inc (NASDAQ: BIIB) FY 2026 Management Update

February 11, 20261 min read

Biogen Inc (BIIB) Sec Form 10K

Biogen Inc (NASDAQ: BIIB) Sec Form 10K

February 7, 20261 min read

Biogen Inc (BIIB) Sec Form 8K

Biogen Inc (NASDAQ: BIIB) Sec Form 8K

February 7, 20261 min read

Analysis

Biogen Shares Rise on Q4 Earnings Beat Despite Lower Revenue Outlook

Shares of Biogen Inc (BIIB) rose 8.53% to $201.18 at close on Friday following the release of fourth-quarter and full-year...

February 6, 20263 min read

AlphaGraphs

Biogen’s Q4 FY25 adj. earnings decline, but beat estimates; revenue down 7%

Biotechnology firm Biogen Inc. (NASDAQ: BIIB) reported lower revenues and adjusted earnings for the fourth quarter of fiscal 2025. The...

February 6, 20261 min read